Clinical Trial Update: Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease [Phase 3]

View source ↗

Summary

This update summarizes Phase 3 trial results for the rivastigmine transdermal patch in probable Alzheimer's disease. It highlights efficacy and safety outcomes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Exelon Patch (rivastigmine transdermal patch)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer's Disease, Dementia, Alzheimer Type | Phase 3 | Status: COMPLETED